Domínguez Wendy Gabriela, Nardi Héctor, Montero Héctor, Vincent Esteban, Corte María Marta, Balogh Gabriela Andrea
Department of Biochemistry and Genetics, Texas A&M University, College Station, TX, USA ; ; CERZOS-CONICET, Centro Científico Tecnológico Bahía Blanca, Bahía Blanca, Argentina.
Exp Ther Med. 2010 Jul;1(4):597-602. doi: 10.3892/etm_00000094. Epub 2010 Jul 1.
The objective of this pilot project was to investigate whether the breast fine needle aspiration (FNA) technique is a useful tool for determining the increased risk of breast cancer in patients with non-palpable breast lesions. FNA is a minimally invasive technique that isolates mammary epithelial cells from breast cells in the suspicious region. In this study, two FNA samples were collected from 12 patients. The level of HER2/neu expression at the mRNA level (in serum) was measured in each patient. As gene amplification is characteristic of cancer cells and may assist in diagnosis and prognostic assessment, it is crucial that gene amplification of HER2/neu in patients with non-palpable breast lesions is compared to breast biopsy results. In serum, the level of HER2/neu was determined by ELISA assay. Gene amplification was determined by PCR and confirmed by IHC employing monoclonal ERRB2 in the FNA sample. The results indicate that FNA has a good correlation with breast biopsy. FNA combined with mammographic imaging is a strong tool for determining favorable treatment options for patients.
该试点项目的目的是研究乳腺细针穿刺抽吸（FNA）技术是否是确定不可触及乳腺病变患者患乳腺癌风险增加的有用工具。FNA是一种微创技术，可从可疑区域的乳腺细胞中分离出乳腺上皮细胞。在本研究中，从12名患者中采集了两份FNA样本。测量了每位患者血清中HER2/neu mRNA水平的表达。由于基因扩增是癌细胞的特征，可能有助于诊断和预后评估，因此将不可触及乳腺病变患者中HER2/neu的基因扩增与乳腺活检结果进行比较至关重要。在血清中，通过ELISA测定法确定HER2/neu的水平。通过PCR确定基因扩增，并在FNA样本中采用单克隆ERRB2通过免疫组化进行确认。结果表明，FNA与乳腺活检具有良好的相关性。FNA与乳腺钼靶成像相结合是为患者确定有利治疗方案的有力工具。
